English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the present study, we report the metallation, characterization,  in vitro  and  in vivo  studies comparing  67 Ga/ 64 Cu-radiolabeled bivalent peptide ligands as targeting probes with the capability of targeting the  α   v   β  3  integrin or the gastrin releasing peptide receptor (GRPR) for preclinical and clinical use in single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging of prostate tumors. The ligand precursor, [RGD-Glu-6-Ahx-RM2] (RGD: Arg-Gly-Asp; Glu: glutamic acid; 6-Ahx: 6-amino hexanoic acid; RM2: D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 ), was conjugated to a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) bifunctional chelator (BFCA), purified by reversed-phase high-performance liquid chromatography (RP-HPLC), characterized via electrospray ionization-mass spectrometry (ESI-MS), and radiolabeled with  67 Ga or  64 Cu. The  in vitro  investigations of the binding affinities of the natural-metallated ligands for the GRPR or the  α   v   β  3  integrin were conducted via competitive displacement binding assays in human prostate PC-3 and glioblastoma U87-MG cell lines. Following stability investigations via RP-HPLC, the  in vivo  evaluations of the Ga 67 /Cu 64 -radiolabeled ligands were performed in CF-1 mice and SCID mice bearing PC-3 tumors. The  in vitro  studies of the natural-metallated ligands showed high binding affinities for the GRPR (7.78 ± 2.42, 8.64 ± 2.16 nM; Ga, Cu respectively) and moderate binding affinity for the  α   v   β  3  integrin receptor (307 ± 40.0, 308  ±  42.6 nM; Ga, Cu respectively).  In vivo  biodistribution studies displayed high tumor uptake (7.44 ± 1.09, 10.85 ±4.02% ID/g at 1 h post-intravenous injection;  67 Ga,  64 Cu respectively) and prolonged tumor retention (4.89 ± 1.11, 4.09 ±0.96% ID/g at 24 h post-intravenous injection;  67 Ga,  64 Cu respectively) in PC-3 tumor-bearing mice. Micro-single photon emission computed tomography (microSPECT) and micro-positron emission computed tomography (microPET) molecular imaging studies produced high-quality, high-contrast images in PC-3 tumor-bearing mice at 18 h post-intravenous injection. Both radiolabeled ligands show satisfactory tumor uptake and retention in PC-3 tumor-bearing mice. However, [RGD-Glu-( 67 Ga-DO3A)-6-Ahx-RM2] demonstrates superior pharmacokinetic profiles to [RGD-Glu-( 64 Cu-DO3A)-6-Ahx-RM2], presumably due to more favorable  in vivo  stability.

radiochimica acta

Molecular imaging investigations of a  67 Ga/ 64 Cu labeled bivalent ligand, [RGD-Glu-(DO3A)-6-Ahx-RM2], targeting GRPR/ α   v   β  3  biomarkers: a comparative study